Although FOLFIRINOX does not directly target KRAS, this combination chemotherapy protocol which is primarily used to treat PDAC, also activates arginine metabolism, highlighting the role of metabolic reprogramming in the development of therapy resistance in pancreatic cancer. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.